Repligen Corporation $RGEN Holdings Raised by Slow Capital Inc.

Key Points

• Slow Capital Inc. increased its ownership of Repligen Corporation by 8.2%, now holding 35,565 shares worth approximately $4,424,000.
• Several analysts have given Repligen a consensus rating of "Moderate Buy" with a target price of $168.08, while Royal Bank Of Canada set a price objective of $205.00.
• Repligen reported a negative net margin of 2.05% for the last quarter, missing EPS estimates, but its revenue increased by 14.8% year-over-year, reaching $182.37 million.

Slow Capital Inc. raised its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 8.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,565 shares of the biotechnology company's stock after buying an additional 2,688 shares during the period. Slow Capital Inc. owned approximately 0.06% of Repligen worth $4,424,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Alliance Wealth Advisors LLC UT lifted its stake in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 89 shares in the last quarter. State of Michigan Retirement System grew its holdings in shares of Repligen by 0.8% during the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after acquiring an additional 100 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Repligen by 0.7% during the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after purchasing an additional 100 shares during the last quarter. State of Wyoming increased its position in Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock worth $297,000 after purchasing an additional 115 shares during the last quarter. Finally, Signaturefd LLC raised its stake in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Weiss Ratings restated a "sell (d)" rating on shares of Repligen in a report on Saturday, September 27th. HSBC began coverage on Repligen in a research report on Wednesday, October 1st. They issued a "buy" rating and a $150.00 price target on the stock. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a report on Tuesday, July 22nd. Finally, Barclays lifted their target price on Repligen from $150.00 to $160.00 and gave the stock an "overweight" rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $168.08.

Repligen Stock Performance

Shares of NASDAQ:RGEN opened at $150.10 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The business's fifty day moving average price is $122.99 and its two-hundred day moving average price is $125.35. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of -600.38, a price-to-earnings-growth ratio of 2.74 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the firm posted $0.40 EPS. The firm's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Activity

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.